BRPI0910464A2 - estimulação de uma resposta imune por enantiômeros de lipídios catiônicos - Google Patents

estimulação de uma resposta imune por enantiômeros de lipídios catiônicos

Info

Publication number
BRPI0910464A2
BRPI0910464A2 BRPI0910464A BRPI0910464A BRPI0910464A2 BR PI0910464 A2 BRPI0910464 A2 BR PI0910464A2 BR PI0910464 A BRPI0910464 A BR PI0910464A BR PI0910464 A BRPI0910464 A BR PI0910464A BR PI0910464 A2 BRPI0910464 A2 BR PI0910464A2
Authority
BR
Brazil
Prior art keywords
enantiomers
stimulation
immune response
cationic lipid
lipid
Prior art date
Application number
BRPI0910464A
Other languages
English (en)
Inventor
Ann Vasievich Elizabeth
Bedu-Addo Frank
Conn Gregory
Toney Kenya
Huang Leaf
Chen Weihsu
Original Assignee
Pds Biotechnolgoy Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pds Biotechnolgoy Corp filed Critical Pds Biotechnolgoy Corp
Publication of BRPI0910464A2 publication Critical patent/BRPI0910464A2/pt
Publication of BRPI0910464B1 publication Critical patent/BRPI0910464B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0910464-0A 2008-04-17 2009-04-14 Uso de uso de um lipídio catiônico quiral consistindo de r-dotap a preparação de composição farmacêutica BRPI0910464B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4583708P 2008-04-17 2008-04-17
US61/045,837 2008-04-17
PCT/US2009/040500 WO2009129227A1 (en) 2008-04-17 2009-04-14 Stimulation of an immune response by enantiomers of cationic lipids

Publications (2)

Publication Number Publication Date
BRPI0910464A2 true BRPI0910464A2 (pt) 2018-03-27
BRPI0910464B1 BRPI0910464B1 (pt) 2021-08-10

Family

ID=41199446

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910464-0A BRPI0910464B1 (pt) 2008-04-17 2009-04-14 Uso de uso de um lipídio catiônico quiral consistindo de r-dotap a preparação de composição farmacêutica

Country Status (13)

Country Link
US (4) US9789129B2 (pt)
EP (1) EP2276495B1 (pt)
JP (1) JP5971945B2 (pt)
CN (2) CN102137675A (pt)
AU (1) AU2009236306B2 (pt)
BR (1) BRPI0910464B1 (pt)
CA (1) CA2721366C (pt)
ES (1) ES2712505T3 (pt)
IL (1) IL208713A (pt)
PL (1) PL2276495T3 (pt)
RU (1) RU2530555C2 (pt)
TW (1) TWI449534B (pt)
WO (1) WO2009129227A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
WO2011109294A1 (en) * 2010-03-01 2011-09-09 Dicerna Pharmaceuticals, Inc. Lipid delivery formulations
JP2011184344A (ja) * 2010-03-08 2011-09-22 Kao Corp p21発現促進剤
NZ606591A (en) 2010-07-06 2015-02-27 Novartis Ag Cationic oil-in-water emulsions
HRP20250981T1 (hr) 2011-05-24 2025-10-24 BioNTech SE Individualizirana cjepiva protiv raka
EP3456316A1 (en) 2011-07-06 2019-03-20 GlaxoSmithKline Biologicals S.A. Cationic oil-in-water emulsions
CN103781470A (zh) 2011-07-06 2014-05-07 诺华股份有限公司 包含核酸的水包油乳液
ES2689799T3 (es) * 2011-09-12 2018-11-15 Pds Biotechnology Corporation Formulaciones de vacunas particuladas
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
AU2013274235B2 (en) * 2012-06-15 2018-01-18 Samir N. Khleif Cationic lipid vaccine compositions and methods of use
AU2013317805B2 (en) * 2012-09-21 2018-07-26 Pds Biotechnology Corporation Improved vaccine compositions and methods of use
EP2925348B1 (en) 2012-11-28 2019-03-06 BioNTech RNA Pharmaceuticals GmbH Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
AU2014365888B2 (en) * 2013-12-16 2018-12-06 Merck Patent Gmbh Survivin-directed cancer vaccine therapy
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
JP2019500021A (ja) * 2015-11-13 2019-01-10 ピーディーエス バイオテクノロジー コーポレイションPds Biotechnology Corporation 樹状細胞療法においてex vivoでの抗原のプロセシングと提示を亢進させるための合成ベクターとしての脂質
WO2018067822A1 (en) * 2016-10-05 2018-04-12 Pds Biotechnology Corporation Methods to alter the tumor microenvironment for effective cancer immunotherapy
US10874733B2 (en) * 2016-10-31 2020-12-29 Eyegene Inc. Composition for enhancing immunity comprising immune modulator and cationic liposome, and use of same
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
CN111655238A (zh) 2017-12-05 2020-09-11 Pds生物科技公司 用于刺激i型干扰素基因的包括阳离子脂质的方法和组合物
JP7813226B2 (ja) * 2019-11-18 2026-02-12 ザ・チルドレンズ・メデイカル・センター・コーポレーシヨン がん免疫療法のために常在型樹状細胞を超活性化する刺激
EP4247493A4 (en) * 2020-11-20 2024-10-09 PDS Biotechnology Corporation METHODS AND COMPOSITIONS CONTAINING CATIONIC LIPIDS FOR IMMUNOTHERAPY BY DIRECT TUMOR INJECTION
EP4604990A2 (en) * 2022-10-19 2025-08-27 PDS Biotechnology Corporation Novel t cell activating immunotherapeutic for treatment of mucin 1 protein expressing human cancers

Family Cites Families (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2167480A (en) 1927-11-02 1939-07-25 Rca Corp Signaling
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
JPS6440808A (en) 1987-08-05 1989-02-13 Canon Kk Zoom lens
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6214804B1 (en) 1989-03-21 2001-04-10 Vical Incorporated Induction of a protective immune response in a mammal by injecting a DNA sequence
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US6183745B1 (en) 1990-12-12 2001-02-06 The University Of Queensland Subunit papilloma virus vaccine and peptides for use therein
WO1993003709A1 (en) 1991-08-16 1993-03-04 Vical, Inc. Composition and method for treating cystic fibrosis
JP3738395B2 (ja) 1991-08-26 2006-01-25 エピミューン,インコーポレイティド Hla−制限型b型肝炎ウィルスのctlエピトープ
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
IL105554A (en) 1992-05-05 1999-08-17 Univ Leiden Peptides of human papillomavirus for use in preparations elicit a human T cell response
CA2134773A1 (en) 1992-06-04 1993-12-09 Robert J. Debs Methods and compositions for in vivo gene therapy
US7105574B1 (en) 1999-03-26 2006-09-12 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
US9266930B1 (en) 1993-03-05 2016-02-23 Epimmune Inc. Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions
AU702517B2 (en) 1993-08-06 1999-02-25 Epimmune, Inc. Cloning and characterization of the complete MAGE-1 gene
AUPM500494A0 (en) 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity
FR2726764B1 (fr) 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc Adjuvant pour composition vaccinale
US6008202A (en) 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
FR2732895B1 (fr) 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
EP0840622A4 (en) 1995-07-21 2003-01-02 Aventis Pharma Inc ADENO-ASSOCIATED VIRUS LIPOSOMES AND THEIR USE FOR THE TRANSFECTION OF DENDRITIC CELLS FOR THE STIMULATION OF SPECIFIC IMMUNITY
JP2001503735A (ja) 1996-07-03 2001-03-21 ユニバーシティ オブ ピッツバーグ 親水性活性試薬のためのエマルジョン処方物
US7001614B2 (en) 1996-08-19 2006-02-21 The United States Of America As Represented By The Department Of Health And Human Services Liposome complexes for increased systemic delivery
US7288266B2 (en) 1996-08-19 2007-10-30 United States Of America As Represented By The Secretary, Department Of Health And Human Services Liposome complexes for increased systemic delivery
US20030229040A1 (en) 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
EP1146907A2 (en) 1999-02-05 2001-10-24 Genzyme Corporation Use of cationic lipids to generate anti-tumor immunity
CA2363141C (en) 1999-02-26 2010-04-06 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
JP4800485B2 (ja) 1999-03-26 2011-10-26 バイカル インコーポレイテッド ポリヌクレオチドベースのワクチンに対する免疫応答を増強するためのアジュバント組成物および方法
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
JP5117648B2 (ja) 1999-04-20 2013-01-16 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア カチオン性peg脂質および使用方法。
US6649170B1 (en) 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
FR2794370B1 (fr) 1999-06-03 2003-10-17 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
EP1185662B1 (fr) 1999-06-10 2011-03-02 Merial Vaccins adn pour les chiens
CA2309313A1 (en) 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation of the immune response by human dendritic cell manipulation
EP1214097B3 (en) 1999-09-16 2011-07-20 Eisai Inc. Nucleic acids encoding polyepitope polypeptides
US20030008813A1 (en) 1999-12-17 2003-01-09 Felgner Philip L. Intracellular protein delivery compositions and methods of use
US20010026937A1 (en) 2000-01-11 2001-10-04 Juha Punnonen Monocyte-derived dendritic cell subsets
EP1257565A4 (en) * 2000-02-01 2005-04-06 Austin Research Inst DERIVED FROM MUCIN-1 ANTIGENE AND ITS USE IN IMMUNOTHERAPY
WO2001080900A2 (en) 2000-04-20 2001-11-01 The University Of British Columbia Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane
AU2001297693A1 (en) 2000-12-08 2002-09-12 Coley Pharmaceutical Gmbh Cpg-like nucleic acids and methods of use thereof
EP1355628A2 (en) 2001-02-01 2003-10-29 Board of Regents, The University of Texas System Stabilised polymeric aerosols for pulmonary gene delivery
WO2002077012A2 (en) 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Human papilloma virus immunoreative peptides
FR2824326B1 (fr) 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
US7025987B2 (en) * 2001-05-30 2006-04-11 The Scripps Research Institute Delivery system for nucleic acids
NZ530635A (en) * 2001-06-15 2007-03-30 Nordic Vaccine Technology As Therapeutical vaccination comprising an immunogen and a targeting vehicle comprising a carrier and a antigen silmilar to the first
CA2451846A1 (en) 2001-06-29 2003-01-09 Chugai Seiyaku Kabushiki Kaisha Cancer vaccine comprizing a cancer antigen based on the product of a tumor suppressor gene wt1 and a cationic liposome
JP2004534088A (ja) * 2001-07-06 2004-11-11 スローン−ケッタリング・インスティテュート・フォア・キャンサー・リサーチ 癌のための多価コンジュゲートワクチン
GB0118517D0 (en) 2001-07-30 2001-09-19 Mitsubishi Tokyo Pharm Inc Compound
DE60238864D1 (de) 2001-11-07 2011-02-17 Mankind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
US7598421B2 (en) 2002-05-08 2009-10-06 Ucl Biomedica Plc Materials for the delivery of biologically-active material to cells
AU2003244855A1 (en) 2002-07-05 2004-01-23 Lipoxen Technologies Limited Method to enhance an immune response of nucleic acid vaccination
WO2004014957A1 (en) 2002-08-12 2004-02-19 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (ctl) epitopes
US20050031587A1 (en) 2002-10-04 2005-02-10 Yamanouchi Pharmaceutical Co., Ltd. Immune response induction method
AU2003284239B2 (en) 2002-10-21 2008-08-21 Eisai Inc. Compositions and methods for treating human papillomavirus-mediated disease
SE0301109D0 (sv) 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
JP2007500239A (ja) 2003-05-30 2007-01-11 アルザ・コーポレーシヨン 薬剤の肺投与の方法
WO2005000889A1 (en) 2003-06-05 2005-01-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides for the treatment of prostate and breast cancer
US7906122B2 (en) 2003-06-18 2011-03-15 Yissum Research Development Company Of The Hebrew University Of Jersusalem Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination
US8242089B2 (en) 2003-06-18 2012-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids polyalkylamine conjugates for use in transfection
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
WO2005014110A1 (en) 2003-07-22 2005-02-17 Cytos Biotechnology Ag Cpg-packaged liposomes
JP5097400B2 (ja) 2003-09-03 2012-12-12 デンドリセラピューティクス、インク. 複合ワクチン
US20050112559A1 (en) * 2003-09-29 2005-05-26 The Chinese University Of Hong Kong Compositions and methods for diagnosing and preventing severe acute respiratory syndrome (SARS)
SG133594A1 (en) 2003-12-10 2007-07-30 Canji Inc Methods and compositions for treatment of interferon-resistant tumors
CN1559607A (zh) 2004-02-20 2005-01-05 �й�ũҵ��ѧ 一种核酸物质与蛋白质类组合物及其生产方法和在免疫调节中的应用
WO2005097181A1 (en) 2004-04-05 2005-10-20 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
US7303881B2 (en) 2004-04-30 2007-12-04 Pds Biotechnology Corporation Antigen delivery compositions and methods of use
EP1781593B1 (en) 2004-06-07 2011-12-14 Protiva Biotherapeutics Inc. Cationic lipids and methods of use
KR20070052273A (ko) * 2004-06-30 2007-05-21 아이디 바이오메디컬 코포레이션 오브 퀘벡 코로나바이러스 감염의 치료를 위한 백신 조성물
US20060051405A1 (en) 2004-07-19 2006-03-09 Protiva Biotherapeutics, Inc. Compositions for the delivery of therapeutic agents and uses thereof
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
CA2589992C (en) 2004-12-13 2014-04-22 Peplin Research Pty Ltd Treatment of solid cancers
US20060159738A1 (en) * 2004-12-14 2006-07-20 Applera Corporation Cationic liposomes and methods of use
KR20080012825A (ko) 2005-01-21 2008-02-12 인트로겐 테라페티스, 인코퍼레이티드 표적 세포가 치료적 및 예방적 핵산에 지속 노출되게 하는국소 투여
WO2007149062A2 (en) 2005-03-14 2007-12-27 Board Of Regents, The University Of Texas System Bioactive fus1 peptides and nanoprticle-polypeptide complexes
JP4516147B2 (ja) 2005-03-18 2010-08-04 ヴェーデクス・アクティーセルスカプ 補聴器用遠隔制御システム
EP1882031B1 (en) 2005-04-08 2017-11-08 Argos Therapeutics, Inc. Dendritic cell compositions and methods
EP1877088B1 (en) 2005-04-11 2014-12-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Vaccine against pandemic strains of influenza viruses
US20060275777A1 (en) 2005-06-03 2006-12-07 Waelti Ernst R Novel strategies for protein vaccines
WO2007022152A2 (en) 2005-08-15 2007-02-22 The Research Foundation Of State University Of New York Lipid nano particulates containing antigens as cancer vaccines
US20110305713A1 (en) 2005-10-21 2011-12-15 Medical College Of Georgia Research Institute, Inc Methods and compositions to enhance vaccine efficacy by reprogramming regulatory t cells
JP5215865B2 (ja) 2005-11-22 2013-06-19 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド ノロウイルス抗原およびサポウイルス抗原
US8802419B2 (en) * 2006-03-02 2014-08-12 University Of Massachusetts Modified pathogens for use as vaccines
JP2007238559A (ja) 2006-03-10 2007-09-20 Nagoya City Univ 未成熟樹状細胞活性化剤及びその使用
EP2013230A2 (en) 2006-04-21 2009-01-14 Transgene S.A. Hpv-16-based papillomavirus vaccine
US20080014251A1 (en) 2006-07-14 2008-01-17 Advanced Vascular Dynamics Hemostatic compound and its use
EP1894941A1 (en) 2006-09-01 2008-03-05 Institut Pasteur Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US20100099745A1 (en) 2006-10-18 2010-04-22 Suryaprakash Sambhara Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors
KR100817024B1 (ko) 2006-11-09 2008-03-26 재단법인 목암생명공학연구소 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CA2688346A1 (en) 2007-05-23 2008-12-04 Vical Incorporated Compositions and methods for enhancing immune responses to vaccines
US7832751B2 (en) * 2007-06-29 2010-11-16 Harley-Davidson Motor Company Group, Inc. Rear fender assembly
JP5623910B2 (ja) 2007-11-02 2014-11-12 ザ ジョンズ ホプキンス ユニバーシティThe Johns Hopkins University ヒトパピローマウイルス感染症の治療又は予防のための複数型hpvペプチド組成物及び方法
AU2009236306B2 (en) 2008-04-17 2015-04-02 Pds Biotechnology Corporation Stimulation of an immune response by enantiomers of cationic lipids
WO2009142892A1 (en) 2008-05-19 2009-11-26 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
US20100086584A1 (en) 2008-09-18 2010-04-08 Juvaris Biotherapeutics, Inc. VACCINE COMPOSITIONS OF M2e, HA0 AND BM2 MULTIPLE ANTIGENIC PEPTIDES
CA2754826A1 (en) 2009-03-06 2010-09-10 Mount Sinai School Of Medicine Live attenuated influenza virus vaccines comprising microrna response elements
JP5797190B2 (ja) 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス, インコーポレイテッド ワクチン免疫療法
WO2011109294A1 (en) 2010-03-01 2011-09-09 Dicerna Pharmaceuticals, Inc. Lipid delivery formulations
CN102939103A (zh) 2010-03-30 2013-02-20 西奈山医学院 流感病毒疫苗及其应用
US9408914B2 (en) 2010-04-28 2016-08-09 Kyowa Hakko Kirin Co., Ltd. Cationic lipid
AR087380A1 (es) 2011-07-27 2014-03-19 Baylor Res Inst Vacunas de celulas dendriticas (cd) para la terapia del cancer de pancreas
ES2689799T3 (es) 2011-09-12 2018-11-15 Pds Biotechnology Corporation Formulaciones de vacunas particuladas
EP2638896A1 (en) 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
AU2013274235B2 (en) 2012-06-15 2018-01-18 Samir N. Khleif Cationic lipid vaccine compositions and methods of use
AU2013317805B2 (en) 2012-09-21 2018-07-26 Pds Biotechnology Corporation Improved vaccine compositions and methods of use
SG11201510748PA (en) 2013-08-21 2016-03-30 Curevac Ag Composition and vaccine for treating lung cancer
AU2014340201B2 (en) 2013-10-23 2019-02-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
CN104189897A (zh) 2014-05-21 2014-12-10 深圳先进技术研究院 一种树突状细胞高效负载抗原的制备方法
KR102668219B1 (ko) 2015-03-16 2024-05-28 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 Mhc 세포 라이브러리를 이용하여 신규한 면역원성 t 세포 에피토프를 검출하고 신규한 항원-특이적 t 세포 수용체를 단리하는 방법
CN105920599B (zh) 2015-09-17 2020-02-11 武汉生物制品研究所有限责任公司 以阳离子脂质体dotap为佐剂的疫苗及其制备方法
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
WO2018067822A1 (en) 2016-10-05 2018-04-12 Pds Biotechnology Corporation Methods to alter the tumor microenvironment for effective cancer immunotherapy
JP7165652B2 (ja) 2016-10-05 2022-11-04 ピーディーエス バイオテクノロジー コーポレイション 新規hpv16非hla拘束性t細胞ワクチン、その組成物及び使用方法
CN111655238A (zh) 2017-12-05 2020-09-11 Pds生物科技公司 用于刺激i型干扰素基因的包括阳离子脂质的方法和组合物
CN111217918B (zh) * 2020-03-04 2020-11-10 中山大学 一种基于2,4-二氧四氢喋啶合酶的新型冠状病毒s蛋白双区域亚单位纳米疫苗

Also Published As

Publication number Publication date
WO2009129227A1 (en) 2009-10-22
JP5971945B2 (ja) 2016-08-17
IL208713A (en) 2016-10-31
US20110110972A1 (en) 2011-05-12
TWI449534B (zh) 2014-08-21
BRPI0910464B1 (pt) 2021-08-10
TW201000124A (en) 2010-01-01
JP2011518170A (ja) 2011-06-23
CA2721366A1 (en) 2009-10-22
ES2712505T3 (es) 2019-05-13
EP2276495A1 (en) 2011-01-26
US20200330491A1 (en) 2020-10-22
US11801257B2 (en) 2023-10-31
CN102137675A (zh) 2011-07-27
AU2009236306A1 (en) 2009-10-22
US10702541B2 (en) 2020-07-07
IL208713A0 (en) 2010-12-30
RU2530555C2 (ru) 2014-10-10
EP2276495B1 (en) 2018-11-21
RU2010146655A (ru) 2012-05-27
PL2276495T3 (pl) 2019-05-31
CN110075113A (zh) 2019-08-02
US20180015114A1 (en) 2018-01-18
EP2276495A4 (en) 2013-05-15
US20210308157A1 (en) 2021-10-07
CA2721366C (en) 2017-06-06
AU2009236306B2 (en) 2015-04-02
US9789129B2 (en) 2017-10-17

Similar Documents

Publication Publication Date Title
BRPI0910464A2 (pt) estimulação de uma resposta imune por enantiômeros de lipídios catiônicos
BRPI0921927A2 (pt) sensibilização de uma resposta imune
PL2125011T3 (pl) Stymulacja odpowiedzi immunologicznej przez lipidy kationowe
EP3431138C0 (en) BRAIN STIMULATION
BRPI0921255A2 (pt) Melhora das caracteristicas de percepção de bebidas
IT1392910B1 (it) Procedimento per la produzione di lipidi da biomassa
EP2485698A4 (en) WHEELCHAIR SUSPENSION
BRPI1009280A2 (pt) bracadeira de riser
EP2567951A4 (en) CATIONIC LIPID
BRPI1009867A2 (pt) controle de uma máquina elétrica
PT2260053E (pt) Análogos de oxitocina
BRPI0906888A2 (pt) derivado de fenilacetamida
EP2745359A4 (en) GRINDING BRUSH HOLDER
BR112013028190A2 (pt) formulação de suspensão agrícola com base em óleo, suspensão agrícola com base em óleo, e, métodos de aplicação da formulação de suspensão agrícola com base em óleo, e de preparar uma formulação de od
BRPI0917210A2 (pt) exoterma controlada de formulações de cianocrilato
SMT201500268B (it) Derivato di 5-idrossipirimidin-4-carbossammide
BRPI0914316A2 (pt) predição de resposta de terapia antiviral
EP2596349A4 (en) PROCEDURE FOR DETECTING CARDIOVASCULAR DISEASES OR SUFFERING
CU23884B1 (es) Derivados de dibenzotiazepina
IT1397895B1 (it) Procedimento per la compensazione di quadratura
FR2947674B1 (fr) Support de connecteur
EP2339929A4 (en) CEREAL SUSPENSION
BRPI1014069A2 (pt) exoterma controlada de formulações de cianocrilato
FI20115815L (fi) Hissin kannatinelimien kompensointijärjestely
EP2498807A4 (en) COMPOSITIONS, METHODS AND APPLICATIONS FOR STIMULATING IMMUNO REACTIONS

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/04/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.